The changing landscape of survivorship care

Christine Duncan, MD, Dana-Farber Cancer Institute, Boston, MA, describes how survivorship care has changed in recent years with the introduction of new treatment modalities and with a wider range of both malignant and non-malignant conditions treated with stem cell transplantation (SCT). Dr Duncan also highlights the importance of personalized survivorship care. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.